Twist Bioscience Corp (NASDAQ:TWST) SVP Patrick Weiss sold 14,730 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $30.66, for a total value of $451,621.80. The transaction was disclosed in a filing with the SEC, which is available at this link.
NASDAQ:TWST traded up $0.20 during midday trading on Friday, hitting $28.99. 1,407 shares of the company traded hands, compared to its average volume of 273,096. The firm’s fifty day moving average is $29.92 and its 200-day moving average is $26.10. Twist Bioscience Corp has a 12-month low of $12.38 and a 12-month high of $35.95. The firm has a market capitalization of $1.00 billion and a P/E ratio of -1.14. The company has a current ratio of 7.18, a quick ratio of 6.96 and a debt-to-equity ratio of 0.03.
Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.09). Twist Bioscience had a negative net margin of 204.63% and a negative return on equity of 168.45%. The company had revenue of $13.60 million for the quarter, compared to analysts’ expectations of $12.51 million. On average, research analysts expect that Twist Bioscience Corp will post -3.8 EPS for the current fiscal year.
A number of research firms have recently commented on TWST. ValuEngine upgraded Twist Bioscience from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded Twist Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, May 8th. Finally, Evercore ISI began coverage on Twist Bioscience in a research report on Friday, May 31st. They set an “outperform” rating and a $26.66 target price for the company. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Twist Bioscience currently has an average rating of “Buy” and a consensus target price of $26.55.
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Recommended Story: How do candlesticks reflect price movement?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.